Profile Details

Create Project

★★★★★

☆☆☆☆☆

USD 50 /hr

★★★★★

☆☆☆☆☆

Hire Diana A.

Netherlands

USD 50 /hr

MD | Clinical Epidemiology | STATA | Medical Writer | Causal Inference for Clinical & Registry Studies

Profile Summary

I am a physician and PhD candidate with formal training in clinical epidemiology and a strong track record in observational clinical research and registry-based studies. My research focuses on the comparative survival analysis of treatment modalities using causal inference methods in nationwide real-world data. I have extensive experience performing data analyses in STATA and supporting the full manuscript development process from study design and statistical analysis plans to results interpretation and scientific writing. I am particularly experienced in working with large population-based registries and translating complex methodological approaches into clinically meaningful conclusions. My publication portfolio includes first-author and collaborative papers in international peer-reviewed high impact factor (>10) journals, where I performed the study design, data analysis, and manuscript preparation.

Subject Matter Expertise

• ☆ Data Analysis
• ☆ Statistics
• ☆ Study Design
• ☆ Health Data Analysis
• ☆ STATA
• ☆ Dermatology
• ☆ Hematology
• ☆ Hematology-Oncology
• ☆ Leukemia & Lymphoma
• ☆ Public Health
• ☆ Epidemiology
• ☆ Internal Medicine
• ☆ Medical Writing

Services

• Writing
• Data & AI

Writing Medical Writing, Technical Writing

Data & AI Predictive Modeling, Statistical Analysis, Big Data Analytics, Data Processing

Work Experience

Faculteit Medische Wetenschappen/UMCG

- Present

MD PhD candidate

University Medical Center Groningen (UMCG)

April 2023 - Present

MD PhD candidate

Karolinska Institute

March 2026 - September 2026

Education

Medicine

University of Groningen

September 2021 - February 2026

Certifications

• Certification details not provided.

Publications

JOURNAL ARTICLE

Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma @article{298df45b201b481ba5f98636f32c0aab, title = "Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma", abstract = "BACKGROUND: Patients with limited-stage primary testicular lymphoma (PTL) typically receive a multimodal regimen, including 6 cycles of R-CHOP, despite limited evidence. In low-risk diffuse large B-cell lymphoma, de-escalation to 4 R-CHOP cycles has proven non-inferior. It remains unclear whether similar de-escalation is feasible in PTL.METHODS: Patients aged ≥ 18 years with Ann Arbor stage I-II PTL diagnosed between 2014 and 2021 were identified in the Netherlands Cancer Registry. Patients receiving ≥ 3 R-CHOP cycles were included. Outcomes were 5-year progression-free survival (PFS), overall survival (OS), and cumulative incidence function (CIF) of CNS-relapse, with follow-up through February 2024. For comparative analysis patients were limited to stage I disease and were categorized into 3 or ≥ 6 R-CHOP cycles.RESULTS: A total of 144 patients were included (median age 71 years); CNS-relapse occurred in 12 of 17 relapsed patients; 83 \% had stage I disease. A total of 87 stage I patients were included in the comparative analysis. Among these patients, 43 received 3 cycles and 44 received ≥ 6 cycles. Intrathecal methotrexate was administered in 94 \%. No significant differences were observed in baseline characteristics or response rates. The 5-year PFS was 71 \% versus 67 \% (p = 0.82), OS 75 \% versus 68 \% (p = 0.97), and CNS-CIF 12 \% versus 13 \% (p = 0.46) for 3 versus ≥ 6 cycles, respectively.CONCLUSION: In this nationwide cohort, nearly half of stage I PTL patients received 3 R-CHOP cycles without inferior outcomes. These real-world findings suggest de-escalation to 3 cycles may be a safe treatment approach in stage I patients and warrant prospective validation.", keywords = "Population-based, Primary testicular lymphoma, R-CHOP, Survival", author = "Diana Al-Sarayfi and Bult, \{Johanna A A\} and \{de Groen\}, \{Ruben A L\} and \{de Groot\}, \{Fleur A\} and Vermaat, \{Joost S P\} and Djamilla Issa and Arjan Diepstra and Gerwin Huls and Mar Bellido and Wouter Plattel and Mirian Brink and Marcel Nijland", note = "Copyright {\textcopyright} 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.", year = "2025", month = oct, day = "16", doi = "10.1016/j.ejca.2025.115776", language = "English", volume = "229", journal = "European Journal of Cancer", issn = "0959-8049", publisher = "ELSEVIER SCI LTD", } . European Journal of Cancer.

Diana Al-Sarayfi, Johanna A.A. Bult, Ruben A.L. de Groen, Fleur A. de Groot, Joost S.P. Vermaat, Djamilla Issa, Arjan Diepstra, Gerwin Huls, Mar Bellido, Wouter Plattel, et al. (2025). Non-inferior outcome of abbreviated R-CHOP in patients with stage I primary testicular lymphoma . European Journal of Cancer.

D. Al‐Sarayfi, M. Brink, M. E. D. Chamuleau, R. Brouwer, R. S. van Rijn, D. Issa, W. Deenik, G. Huls, R. Mous, J. S. P. Vermaat, et al. (2024). R‐miniCHOP versus R‐CHOP in elderly patients with diffuse large B‐cell lymphoma: A propensity matched population‐based study . American Journal of Hematology.

R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma @article{31e92440a06744c6999578dde36e6eca, title = "R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: A propensity matched population-based study", abstract = "For elderly frail patients with diffuse large B-cell lymphoma (DLBCL), an attenuated chemo-immunotherapy strategy of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-miniCHOP) was introduced as a treatment option as from 2014 onward in the Netherlands. Although R-miniCHOP is more tolerable, reduction of chemotherapy could negatively affect survival compared to R-CHOP. The aim of this analysis was to assess survival of patients treated with R-miniCHOP compared to R-CHOP. DLBCL patients ≥65 years, newly diagnosed in 2014-2020, who received ≥1 cycle of R-miniCHOP or R-CHOP were identified in the Netherlands Cancer Registry, with survival follow-up through 2022. Patients were propensity-score-matched for baseline characteristics. Main endpoints were progression-free survival (PFS), overall survival (OS), and relative survival (RS). The use of R-miniCHOP in DLBCL increased from 2\% in 2014 to 15\% in 2020. In total, 384 patients treated with R-miniCHOP and 384 patients treated with R-CHOP were included for comparison (median age; 81 years, stage 3-4; 68\%). The median number of R-(mini)CHOP cycles was 6 (range, 1-8). The 2-year PFS, OS and RS were inferior for patients treated with R-miniCHOP compared to R-CHOP (PFS 51\% vs. 68\%, p < .01; OS 60\% vs. 75\%, p < .01; RS 69\% vs. 86\%, p < .01). In multivariable analysis, patients treated with R-miniCHOP had higher risk of all-cause mortality compared to patients treated with R-CHOP (HR 1.73; 95\%CI, 1.39-2.17). R-miniCHOP is effective for most elderly patients. Although survival is inferior compared to R-CHOP, the use of R-miniCHOP as initial treatment is increasing. Therefore, fitness needs to be carefully weighed in treatment selection.", author = "D Al-Sarayfi and M Brink and Chamuleau, \{M E D\} and R Brouwer and \{van Rijn\}, \{R S\} and D Issa and W Deenik and G Huls and R Mous and Vermaat, \{J S P\} and A Diepstra and Zijlstra, \{J M\} and \{van Meerten\}, T and M Nijland", note = "{\textcopyright} 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.", year = "2024", month = feb, doi = "10.1002/ajh.27151", language = "English", volume = "99", pages = "216--222", journal = "American Journal of Hematology", issn = "0361-8609", publisher = "Wiley", number = "2", } . American Journal of Hematology.

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma @article{410a767d8aa74fc1a26490c5c7657fa8, title = "R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma", keywords = "ELDERLY-PATIENTS", author = "Diana Al-Sarayfi and Meeuwes, \{Frederik O.\} and Mujde Durmaz and Issa, \{Djamila E.\} and Brouwer, \{Rolf E.\} and Aart Beeker and \{van Rhenen\}, Anna and Mutsaers, \{Pim G. N. J.\} and Bohmer, \{Lara H.\} and \{van der Poel\}, \{Marjolein W. M.\} and \{te Boome\}, Liane and \{van Meerten\}, Tom and Chamuleau, \{Martine E. D.\} and Zijlstra, \{Josee M.\} and Mirian Brink and Marcel Nijland", year = "2022", month = sep, day = "2", doi = "10.1038/s41408-022-00723-4", language = "English", volume = "12", journal = "Blood cancer journal", issn = "2044-5385", publisher = "Nature Publishing Group", number = "9", } . Blood cancer journal.

R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma <head> <META HTTP-EQUIV="Refresh" CONTENT="0;URL=/servlet/useragent"> </head> . Blood Cancer Journal.

OTHER

Successful treatment of hairy cell leukemia variant with obinutuzumab @article{a7664ab08db6474bbb9eedfdc2eb5cba, title = "Successful treatment of hairy cell leukemia variant with obinutuzumab", author = "Diana Al-Sarayfi and Meeuwes, \{Freek O.\} and Munnink, \{Thijs Oude\} and Wouter Plattel and Stefano Rosati and Estella Matutes and Marcel Nijland", year = "2022", month = mar, doi = "10.1007/s00277-021-04559-z", language = "English", volume = "101", pages = "703–704", journal = "Annals of Hematology", issn = "0939-5555", publisher = "Springer", } . Annals of Hematology.